SCHEMBL3068151

SCHEMBL3068151

Cc1nc(-c2ccc(OCCCCl)cc2)oc1C(=O)N1CCCCC1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.48
ALDH1A1 P00352 5/20 0.48
HRH3 Q9Y5N1 8/20 0.47
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TLR9 Q9NR96 3/20 0.43
TLR7 Q9NYK1 2/20 0.43
KCNH2 Q12809 1/20 0.43
RAB9A P51151 2/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
LMNA P02545 1/20 0.42
PPARG P37231 1/20 0.42
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3071083 0.91 HRH3 (0.49) HPGDALDH1A1HRH3KMT2ASMN1; SMN2
SCHEMBL3080613 0.87 HRH3 (0.47) ALDH1A1HRH3KMT2AMEN1SMN1; SMN2
SCHEMBL3066081 0.85 HRH3 (0.61) HRH3KCNH2
SCHEMBL3080950 0.83 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2RAB9ALMNAPPARG
SCHEMBL3078511 0.80 ALDH1A1 (0.67) HPGDALDH1A1HRH3SMN1; SMN2RAB9A
SCHEMBL3079473 0.78 HRH3 (0.50) HPGDALDH1A1HRH3KMT2AMEN1
SCHEMBL3083751 0.77 HRH3 (0.71) HRH3KCNH2
SCHEMBL3080421 0.77 HRH3 (0.71) HRH3KCNH2
SCHEMBL3072192 0.77 HRH3 (0.71) HRH3KCNH2
SCHEMBL3082341 0.77 PPARA (0.48) ALDH1A1HRH3KMT2AMEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses UCB PHARMA, S.A. (BE) 2008-11-06 US claimed
US-7790720-B2 Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses UCB PHARMA, S.A. (BE) 2010-09-07 US disclosed
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses UCB PHARMA, S.A. (BE) 2008-11-06 US disclosed
EP-1866293-A1 COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES UCB Pharma, S.A. (BE) 2007-12-19 EP disclosed
WO-2006103045-A1 COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES UCB PHARMA S.A. (BE) 2006-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses OXER1, OXTR, OGFR HPGD 2325/4885ALDH1A1 305/4885HRH3 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.